
Adjuvia Therapeutics Launches Phase 1 Clinical Trial of ATI-105 for Friedreich’s Ataxia
Adjuvia Therapeutics Doses First Participant in Phase 1 Trial of ATI-105 for Friedreich’s Ataxia Adjuvia Therapeutics, a biotechnology company focused on developing novel treatments for mitochondrial dysfunction and associated diseases,…














